Co-promotion deals are built on a simple idea. One company has a product and not enough reach. Another has a sales force with access to the right prescribers and spare capacity. Put them together and both win. The agreement that makes this work, however, is anything but simple. It allocates promotional effort, compliance responsibility, safety reporting, governance and money between two organizations that each have their own systems, cultures and priorities.
Most alliance disputes do not start over the headline economics. They start over execution: whether the partner delivered the detailing it promised, whether a representative used an unapproved slide, whether an adverse event reported in the field reached the safety database in time. Those questions are answered by obligations buried in schedules and exhibits that nobody reads after the launch meeting.
This article is for alliance managers, commercial operations leads and compliance officers who own co-promotion relationships. It maps the obligations that slip most often, explains why they slip and lays out a practical approach to tracking them across both partners for the life of the deal. The aim is a single shared record that both companies trust, so reviews focus on performance rather than on whose numbers are right.
Obligations inside a typical co-promotion agreement
Structures vary by product, territory and deal stage, but most co-promotion agreements carry commitments in the following areas. Each one needs an owner on both sides.
- Detailing effort, minimum details, call frequency, target prescriber lists and position requirements, often measured quarterly against a shared plan.
- Promotional materials, rules that only materials approved through the lead partner’s medical, legal and regulatory review may be used in the field.
- Safety reporting, duties for both sales forces to forward adverse events and product complaints to the safety function within set timeframes.
- Compliance and transparency, adherence to industry codes, anti-kickback rules and reporting of payments or transfers of value to healthcare professionals.
- Governance and diligence, joint steering committee meetings, commercial plan approvals, performance reviews and termination rights tied to missed targets.
Several of these obligations run in both directions. The lead partner usually owns the brand plan and materials approval, but the co-promoting partner owns its representatives’ conduct, training records and call reporting. When responsibilities overlap, each party can assume the other is handling it. The contract usually says who is responsible. The problem is that nobody translates the contract into a tracker both teams can see. The same pattern shows up in clinical partnerships, covered in the clinical trial agreement automation guide.
In co-promotion, both partners sell one product under one brand, and sales are usually booked by one party. In co-marketing, each partner sells the same molecule under its own brand and books its own sales. The obligations, economics and compliance exposure differ, so confirm which structure you are tracking before building a template.
Why co-promotion obligations drift after signature
The patterns are consistent across therapeutic areas. None of them comes from bad faith. They come from two organizations running the same program on separate systems.
- Call data does not reconcile. Each partner reports details from its own CRM, with different definitions of what counts as a detail, so quarterly effort reviews turn into arguments about data.
- Materials outlive approval. A slide deck is withdrawn or revised by the lead partner, but the co-promoting field force keeps using the old version stored locally.
- Safety handoffs are informal. Representatives know to report adverse events but are unsure which partner’s safety inbox to use or how quickly it must happen.
- Committee decisions go unrecorded. Steering committees agree to change targets or budgets, but the amendment or minutes that make the change binding never get finalized.
- Termination windows pass unnoticed. Rights to terminate for missed detailing targets or change of control have notice periods that expire before anyone checks them.
A five-step approach to tracking co-promotion obligations
Step 1, Abstract the agreement into obligations
Break the agreement and its schedules into discrete obligations, each with a responsible party, frequency, due date and evidence requirement. AI-assisted review can pull candidate obligations from long agreements quickly, and alliance and legal teams then confirm the list before it goes live.
Step 2, Agree shared definitions
Settle what counts as a detail, a target prescriber and a completed call before the first quarterly review. Put the definitions in the tracker next to the obligation so both sales operations teams measure the same thing the same way, and revisit them whenever either partner changes its CRM or call reporting rules.
Step 3, Link materials to approval status
Maintain one register of approved promotional materials with version numbers and withdrawal dates. Give both field forces access to the current list, and set a task to confirm withdrawn items are removed from the co-promoting partner’s systems. A short attestation from each district manager after every withdrawal gives compliance the evidence it needs.
Step 4, Test the safety handoff
Document the reporting path for adverse events and product complaints, including timeframes and contacts, and verify both partners train their representatives on it. Periodic reconciliation between the partners’ safety records confirms nothing is falling through.
Step 5, Run governance on a calendar
Schedule steering committee meetings, plan approvals, diligence reviews and termination notice windows as dated obligations with reminders. Record committee decisions and route any change to targets or economics through a formal amendment. Informal agreements made in a meeting room rarely survive a change in personnel on either side.
Track every co-promotion commitment in one place
See how Aavenir turns alliance agreements into owned, dated obligations with evidence both partners can review.
What good alliance oversight looks like
Mature alliance teams treat the co-promotion agreement as an operating document. Every obligation has a named owner at each partner, a due date and an evidence field showing what was delivered. Quarterly reviews start from a shared view of detailing effort, materials status, safety reconciliation and open governance items, so the meeting is spent on decisions rather than on reconciling spreadsheets. When something slips, the record shows who knew and when, which keeps disputes factual. It also gives executives on both sides a reliable basis for decisions about expanding, restructuring or exiting the partnership. This discipline also pays off when the relationship ends. Termination and wind-down provisions often require return of materials, transition of prescriber relationships and final reconciliation of payments, and an obligation history makes that process far less contentious. Life sciences teams already tracking quality and supply commitments, summarized in the life sciences obligation management datasheet, can extend the same model to commercial alliances without building a separate tool.
Common co-promotion obligations and their evidence
The table shows the evidence alliance managers typically ask for. Exact requirements depend on the agreement, the territory and the applicable codes and laws, so confirm each item with compliance and legal before using it as a standard.
| Obligation | Usual owner | Cadence | Evidence |
|---|---|---|---|
| Minimum detailing effort | Co-promoting partner | Quarterly | Reconciled call data against plan |
| Approved materials only | Lead partner approves, both use | Ongoing | Materials register with versions |
| Adverse event forwarding | Both sales forces | Per event, within set timeframe | Safety intake logs and reconciliation |
| Transfer-of-value reporting | Per agreement allocation | Annual cycle | Payment data and submission records |
| Steering committee governance | Joint | As scheduled | Signed minutes and amendments |
A co-promotion agreement only delivers when both partners execute against the same set of obligations. Break the contract into owned commitments, agree how effort is measured, control materials and safety handoffs and run governance on a calendar. Alliance managers who do this spend less time arguing about data and more time growing the brand.
For related guidance, see Quality agreement obligations pharma teams keep missing, Safety data exchange agreement tracking for PV teams and Licensing milestone payment tracking in biopharma deals.
